CSG Faces Twin Narrative: Founder’s Civilian Fund and Defense Unit’s Karpat Tank Debut

European defense group CSG faces disconnect: record orders vs 51% stock slump after short-seller attack; founder plans €10B civilian fund; Q1 earnings due May 20.

CSG finds itself in a peculiar spot. The European defense group’s order backlog stands at a record €14 billion, up 69% year-on-year, and its pipeline including long-term framework agreements reaches €42 billion. Yet the stock trades at €16.72 — roughly half its January high of €33.81. That disconnect is about to be tested from two very different directions: founder Michal Strnad’s ambitious plan to recycle part of his IPO windfall into a civilian holding, and the group’s own drive to prove it can deliver more than just munitions.

Founder Michal Strnad, meanwhile, is moving to put his personal gains from the January IPO to work. The offering on Euronext Amsterdam raised €3.8 billion including the full greenshoe, making it the largest pure defense IPO on record, and netted Strnad approximately €2.55 billion. He now intends to leverage that into an investment vehicle of up to €10 billion targeting exclusively civilian sectors — media, real estate and waste management. The structure is designed to avoid conflicts of interest with his role as CEO of CSG, with Europe and the United States named as primary geographies.

On the industrial front, CSG is trying to broaden its identity beyond ammunition. At the IDEB 2026 defense exhibition in Bratislava, it unveiled the CFL-120 Karpat, a medium combat platform co-developed with Turkish manufacturer FNSS. The 120mm turret comes from Leonardo, while the chassis is based on Turkish engineering. CSG’s contribution centers on its Slovak industrial base, where serial production is planned. The vehicle tips the scales at 34 tonnes, reaches 70 km/h and has a range of around 450 kilometres. It aims to deliver firepower close to that of a main battle tank — which often exceeds 60 tonnes — but with lower logistics costs and easier deployability. Ammunition stowed outside the crew compartment is intended to improve survivability.

The financial picture, however, remains clouded. All nine analysts covering CSG rate the shares a buy, with JPMorgan targeting €40 and the consensus at €35.40. That bullishness stands in stark contrast to the market’s current mood. The stock gained 1.83% on Monday to close at €16.72, but the broader trend has been sharply negative.

That disconnect stems in large part from a short-seller attack by Hunterbrook Media on May 4. The report accused CSG of merely refurbishing old ammunition stocks and overstating production capacity. Trading was briefly suspended as the stock plunged 13%. CSG has rejected the allegations as false. From the January high of €33.81, the share price has now lost roughly 51%, and over the past 30 days it has fallen more than 23%.

Investors now have two key events on their radar. On May 20, CSG will publish its first quarterly report since the IPO — a critical test of its production guidance for 2026. Management has reaffirmed revenue guidance of above €7 billion for the full year and an operating EBIT margin in the mid-twenties. The first quarter will also provide an update on planned production increases at plants in Slovakia, Spain and Greece, as well as joint artillery munitions ventures in Ukraine. Meanwhile, CSG continues to push into broader defense markets: on May 13 it made an offer to acquire a stake in the Franco-German tank maker KNDS, and the group has already secured $2.5 billion in air defense contracts in Asia.

Ultimately, credibility hinges on execution. The Karpat will not contribute meaningfully to near-term revenues, but it signals CSG’s ambition to become an integrated land systems supplier rather than just a munitions house. Concrete procurement commitments from NATO members or export customers would give that narrative real weight. Until then, the next definitive checkpoint remains the May 20 earnings release — the first independent look at whether the operational momentum can close the gap between analyst optimism and the stock’s painful slide.